Alexion Reports Second Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharmaceuticals (ALXN) PT Raised to $170 at Leerink Partners
July 28, 2017 10:20 AM EDTLeerink Partners raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $170.00 (from $136.00) while maintaining a Outperform rating. ALXN reported Q2 results and delivered a solid revenue and EPS beat vs. consensus. Management highlighted that the biggest contributors to the revenue growth were strong volume... More
Alexion Pharma (ALXN) Tops Q2 EPS by 30c, Sales Beat; Raises Outlook
July 27, 2017 6:31 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $1.56, $0.30 better than the analyst estimate of $1.26. Revenue for the quarter came in at $912 million versus the consensus estimate of $845.53 million.
GUIDANCE:
Alexion Pharma sees FY2017 EPS of $5.40-$5.55, versus the consensus of... More
